Print Page  |  Close Window

Investors

FGEN (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$24.60
Change (%) Stock is Up 0.20 (0.82%)
Volume354,309
Data as of 02/17/17 4:00 p.m. ET
Refresh quote
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs.
Recent Press ReleasesMore »
DateTitle 
02/03/17FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with ChemotherapyPrinter Friendly Version
01/30/17FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in ChinaPrinter Friendly Version
01/20/17Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers SymposiumPrinter Friendly Version
11/08/16FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate UpdatePrinter Friendly Version
Upcoming EventsMore »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources